The purpose of this study is to find the biggest dose of antibody-attached T cells that is safe, to see how long each sort of T cell lasts, to learn what the side effects are and to see whether this therapy might help children with neuroblastoma.

PATIENT TREATMENT Three different dose levels will be evaluated. Three to six patients will be evaluated on each level. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:

Group One

• Day 0 CTLs: 2x10^7 cells/m2 PBMCs: 2x10^7 cells/m2
• Day 14 CTLs: 2x10^7 cells/m2 PBMCs: 2x10^7 cells/m2

Group Two

• Day 0 CTLs: 2x10^7 cells/m2 PBMCs: 2x10^7 cells/m2
• Day 14 CTLs: 1x10^8 cells/m2 PBMCs: 1x10^8 cells/m2

Group Three

• Day 0 CTLs: 1x10^8 cells/m2 PBMCs: 1x10^8 cells/m2
• Day 14 CTLs: 1x10^8 cells/m2 PBMCs: 1x10^8 cells/m2

Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• All patients with recurrent or refractory advanced stage neuroblastoma.
• Patients must be EBV sero-positive.
• Patients must have a life expectancy of at least 12 weeks.
• Patients must have recovered from the toxic effects of all prior chemotherapy before entering this study.
• Patients must not be currently receiving any investigational agents or have not received any tumor vaccines within the previous six weeks.
• Patients must have bilirubin less than 3 times the upper limit of normal.
• Patients must have AST less than 5 times the upper limit of normal.
• Patients must have serum creatinine less than 3 times upper limit of normal.
• Patients must have Karnofsky score of > 60% if >/= 10 years old or Lansky performance score of greater than 60% if /=15% expression of 14g2a.zeta determined by flow-cytometry.
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded. The male partner should use a condom.
• Patients must not be pregnant or lactating.
• Patients must not have tumor in a location where enlargement could cause airway obstruction.

Exclusion Criteria:

• Patients not meeting eligibility criteria.